Company ProfilePremium

Rhythm Biosciences Limited

Company Profile Analysis

Ticker: RHY.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Rhythm Biosciences Limited - Company showcase

Year Founded & Workforce

2017

Rhythm Biosciences Limited logo

Rhythm Biosciences Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Rhythm Biosciences Limited Overview

Rhythm Biosciences is a Melbourne-based, commercial-stage precision diagnostics micro-cap that has spent eight years converting CSIRO-originated science into two marketable cancer-detection platforms. Its flagship, ColoSTAT, is a blood test measuring five protein biomarkers to indicate the likelihood of colorectal cancer, now offered in Australia as an in-house IVD from the company's NATA/ISO 15189-accredited Parkville laboratory, with ordering embedded in GP software and samples collected through 4Cyte Pathology's network. Its second platform, geneType, acquired out of administration in December 2024 for A$0.52M cash, provides polygenic and clinical risk assessment across nine tests and gives Rhythm a US footprint. FY26 marked the transition from development to first sales (A$85,339), but the business remains deeply loss-making (FY26 loss A$5.93M), carries a going-concern material uncertainty, and depends on continued equity funding. The investment case rests on converting clinical interest, an NHS England evaluation and reimbursement work into scalable test volumes.


Company's own description (FY26 Annual Report / Appendix 4E)

In its FY26 Directors' Report the company describes itself as an innovative Australian, publicly listed medical diagnostics company focused on delivering simple, affordable blood tests for the accurate detection of cancers, providing physicians with accurate and reliable diagnostic tools. The Directors characterise FY26 as the year in which Rhythm moved from development to commercialisation, with both diagnostic platforms — ColoSTAT and geneType — recording clinical sales. In its Q4 FY26 activities report, the company described itself as a commercial-stage precision diagnostics company. Segment Note 19 states the group operates in one business — the development and commercialisation of cancer diagnostic tests — in Victoria, Australia and the United States.

Independent characterisation

Rhythm is best understood as a laboratory-service diagnostics company in its first year of revenue, rather than a kit manufacturer. Its current Australian model has four elements:

  1. Clinician demand generation — GPs and specialists order ColoSTAT, increasingly via an electronic request form integrated into MedicalDirector (live 1 August 2026), supported by a direct ColoSTAT Access Program and an Ausdoc-delivered awareness campaign targeting approximately 20,000 GPs (July 2026).

  2. Sample logistics via partners — patients have blood drawn at 4Cyte Pathology collection centres (agreement signed February 2026; network covering more than 1,000 centres across NSW, Victoria and Queensland, with 100+ sites activated for ColoSTAT by August 2026). 4Cyte operates on a per-test basis with no upfront payments or minimum commitments.

  3. Centralised testing — all ColoSTAT samples are analysed at Rhythm's own ISO 15189:2022/NATA-accredited Parkville laboratory, under a TGA in-house IVD notification accepted in August 2026.

  4. Direct patient billing — Rhythm invoices patients directly; ColoSTAT is not currently funded by Medicare (company announcement, 7 October 2026). The health-economic model published that day assumed A$250 per test.

The geneType platform runs a parallel B2B2C and channel-partner model: tests are ordered through healthcare providers and genetic counsellors, and distributed via partners (Catch Bio and Cancer IQ in the US; an unnamed Southeast Asian distributor launching in the Philippines; the Australian Genome Research Facility for domestic scale-up).

Internationally, the company is pursuing a technology-transfer / laboratory-partner model, in which third-party laboratories run ColoSTAT using Rhythm's reagent kits (manufactured under contract by US-based Quansys Biosciences). The completion of technology transfer to the NHS Southern Hub laboratory in September 2026 is the first proof that a third party can run the assay.

Revenue model mix

Revenue typeStatus (FY26)Comment
Product (kit sales)Not yet materialKit sales to third-party labs are the intended international model; none disclosed as revenue in FY26
Service (laboratory testing)PrimaryColoSTAT and geneType tests performed in-house and billed per test
Subscription—Not applicable
Licensing / royaltiesNone receivedRhythm is a licensee (pays CSIRO a 2% royalty on ColoSTAT sales per IPO-era disclosure)
Government income (R&D tax incentive)Dominant non-operating inflowA$1.576M received in FY26; A$3.166M in FY25

The statutory P&L does not split sales revenue by platform. Total sales revenue was A$85,339 in FY26 versus A$25,126 in FY25 (the latter entirely from geneType following acquisition).

Value-chain position

Rhythm sits in the assay development, regulatory and testing-service layer. It outsources reagent kit manufacture (Quansys Biosciences, USA, multi-year agreement with two years of fixed pricing; previously Biotem, France, appointed December 2020), outsources phlebotomy and specimen logistics (4Cyte Pathology), and relies on GP software vendors (MedicalDirector) for ordering. It retains all IP and data, the accredited laboratory, the algorithm, and the clinical/regulatory dossier.

Customer types and end-markets

Customer / payerProductMarket
General practitioners (referrers)ColoSTATAustralia (eastern states first)
Specialists (gastroenterologists, colorectal surgeons)ColoSTATAustralia
Patients (self-pay)ColoSTAT, geneTypeAustralia
Public health systems (prospective)ColoSTATUK (NHS England evaluation), Australian public hospitals (health-economic case)
Genetic counsellors, cliniciansgeneTypeAustralia, US
Digital health / prevention platformsgeneTypeUS (Catch Bio, Cancer IQ)
DistributorsgeneTypeSoutheast Asia (Philippines initial)

End-markets: colorectal cancer triage and screening (symptomatic and screening-hesitant populations), and polygenic risk assessment for cancers and chronic disease.

Strategy

Stated strategy (themes from FY26 Annual Report, quarterly reports and investor presentations)

Management's framing centres on four themes:

  1. "From research to revenue." The January 2026 quarterly headline described ColoSTAT's business update in these terms, and the April 2026 quarterly declared Rhythm no longer a development-stage company but a commercial diagnostics business with two revenue-generating platforms.

  2. Capital-efficient commercialisation via partners. Per-test arrangements (4Cyte), contract manufacturing (Quansys), software integration (MedicalDirector) and distribution partners (geneType) avoid fixed-cost build-out.

  3. Evidence and reimbursement. Real-world data from the Access Program, peer-reviewed publication, health-economic modelling (October 2026) and the NHS evaluation are intended to support future public funding.

  4. Platform synergy. geneType's enhanced CRC risk model is positioned to identify high-risk individuals for ColoSTAT triage, creating a "risk assessment → detection" pathway.

The FY26 Directors' Report states Rhythm enters FY2027 with a clear operational focus on converting clinical interest into sustained test volumes. Note 13 adds that the company is not actively pursuing additional investments in the short term while it integrates and grows existing businesses.

Strategic initiatives — last 24 months

InitiativeDateDescriptionStatus
geneType acquisitionDec 2024–Jan 2025Distressed acquisition from GTG administratorsCompleted; NATA reinstated
ColoSTAT Gen2 multiplexDec 2024Single-reaction kit lowering COGSBeta delivered; supply contracted
ISO 15189:2022 updateDec 2025Laboratory accreditationAchieved
NHS England evaluationDec 2025–ongoingMulti-phase independent evaluation at Southern HubPhase 1 (tech transfer) complete Sep 2026
ColoSTAT Access ProgramFeb 2026Capped program for real-world evidenceOngoing; repeat clinical ordering reported
Quansys manufacturingFeb 2026Multi-year supply; two years fixed pricingActive
4Cyte collection networkFeb 2026 (expanded twice)1,000+ centres available; 100+ activatedActive
NATA accreditation of ColoSTAT serviceMar 2026Clinical testing accreditationAchieved
geneType SE Asia distributionMar 2026Philippines initial marketFirst sale achieved
AGRF partnershipQ3 FY26Domestic geneType scale-upActive
Catch Bio (US)Dec 2025Marketing of geneType to US membersActive
Cancer IQ (US)FY26Platform partnership for geneTypeActive
Memorial Sloan Kettering collaborationH1 FY26Scientific validation of geneTypeActive
BIO International 2026Jun 2026Partnering meetingsMultiple opportunities reported
GP awareness campaign (Ausdoc)Jul 2026~20,000 GPs, >50% of eastern-states GP audienceRunning
TGA in-house IVD notificationAug 2026Regulatory compliance for in-house useAccepted
MedicalDirector integrationAug 2026Electronic orderingLive; further integrations planned
Health-economic studyOct 2026Public hospital colonoscopy demand modelPublished
US reimbursement strategy for geneTypeFY27In developmentPlanned

ESG and cost programs

No formal sustainability targets or quantified cost-reduction program have been announced. The FY26 risk discussion notes management can scale back R&D and other activities if required to preserve liquidity.

Management guidance and targets

ItemGuidanceSource
Cash runwayCash reserves expected to fund operations through Q4 FY27Q4 FY26 Appendix 4C (30 Jul 2026)
geneTypeStronger sales growth expected in Q3 FY26 from partnershipsQ2 FY26 Appendix 4C
ColoSTAT Gen2Commercial launch targeted late FY26FY25 Annual Report
Implied revenue target (incentive hurdle)A$1.5M revenue by June 2027; A$0.15M in three other countriesFY26 Remuneration Report
Formal revenue or earnings guidanceNot provided—

Products & Services

ColoSTAT platform

Product / serviceDescription and capabilitiesTarget customerLaunch / versionPricing
ColoSTAT test (laboratory-developed / in-house IVD)Venous blood test measuring five specific protein biomarkers that rise or fall in the presence of colorectal tumours; result indicates likelihood of CRC. Positioned as a triage test for symptomatic patients and as an alternative for people unable or unwilling to use stool-based FIT screening. Historically indicated for adults aged 40–85 at average riskGPs, specialists, symptomatic patients, screening-hesitant individualsFirst commercial sale March 2026; NATA accreditation of clinical testing service March 2026; TGA in-house IVD notification accepted August 2026Patient self-pay; not Medicare funded. Health-economic study assumed A$250 per test (Oct 2026). Access Program initially provided free tests to establish workflows
ColoSTAT Gen2 multiplex kitCombines the previously separate biomarker assays into a single reaction per patient sample, lowering cost of goods; beta release candidate kits delivered December 2024. FY25 annual report targeted commercial launch in late FY26Rhythm's own laboratory; third-party laboratories (e.g., NHS Southern Hub)Beta delivered Dec 2024; commercial supply via Quansys from Feb 2026—
ColoSTAT Access ProgramCapped direct-referral program (initially 20 participating clinicians nationally) designed to generate real-world evidence for reimbursement and partner discussionsEarly-adopter cliniciansFirst physician enrolled 11 Feb 2026Initial tests free; transitioning to paid
UKCA-marked ColoSTAT kitConformity with European IVD Directive 98/79/EC and UKCA requirements, enabling marketing in Great BritainUK laboratories / NHSUKCA granted 2023—
ColoSTAT electronic orderingTest request form integrated into MedicalDirector GP clinical software; further integrations in progressGPsLive 1 Aug 2026Not applicable

Clinical performance data: Study 7 (815 patients, 11 Australian sites) reported 81% sensitivity and 91% specificity (company announcement, 2022). In FY26 the clinical performance data were published in a peer-reviewed journal (FY26 Directors' Report).

geneType platform

Product / serviceDescriptionTarget customerStatus
geneType Cancer Risk Assessment (multi-cancer)Integrates genetic profile (polygenic risk score from saliva/buccal sample), clinical factors and family history to estimate risk across up to six cancersClinicians, genetic counsellors; US prevention platformsMarketed in Australia and US
geneType Colorectal Cancer Risk Test (enhanced, Jan 2026)Next-generation CRC risk model delivered ahead of schedule in Q2 FY26; positioned to identify high-risk individuals who can then be triaged with ColoSTATClinicians; ColoSTAT cross-sellReleased Jan 2026
geneType Breast Cancer RiskPolygenic + clinical breast cancer risk assessmentWomen, cliniciansMarketed
geneType Ovarian Cancer RiskRisk model validated by Harvard Medical School researchers (announced Q2 FY26)Women, cliniciansMarketed
geneType Prostate, Pancreatic, Melanoma risk testsPolygenic risk assessment for each cancer typeCliniciansMarketed
geneType Cardiometabolic testsCoronary artery disease, atrial fibrillation, type 2 diabetes riskCliniciansMarketed
Molecular genetics servicesDNA extraction, predictive genetic testing, primary/secondary/tertiary bioinformatic analysisResearch and clinical clientsInherited from Genetic Technologies

The March 2026 Southeast Asian distribution announcement describes the portfolio as nine clinically validated genetic risk tests. Pricing for geneType tests is not publicly disclosed in the documents reviewed.

Pipeline / earlier-stage programs

ProgramStatus
Breast cancer protein biomarkers (blood)Preliminary assessment reported positive results (pre-2024); effectively returned to pre-clinical following 2023 strategic review
Pan-cancer / multi-cancer platformProgram commenced pre-2023 per November 2022 Bell Potter presentation; current status not publicly disclosed
geneType US reimbursement strategyIn development (Q4 FY26 activities report)

Financial Narrative

Income statement: notes and sources

Notes: FY2025–FY2026 line items from FY26 Appendix 4E (P&L, Notes 3, 4, 6). Net loss and basic EPS for FY2022–FY2024 from the five-year table in the FY26 Remuneration Report. FY2023–FY2024 total income from aggregator (stoxray) data. FY2022–FY2024 weighted average shares are derived (net loss ÷ basic EPS) and therefore approximate. EBITDA = loss + D&A + finance expense − interest income (analyst calculation). Revenue CAGR over five years is not meaningful because the base year has nil sales; FY25→FY26 sales growth was 239.6%. Gross, operating and net margins on sales revenue are not meaningful (FY26 gross margin on sales −322%; net loss equal to ~69x sales).

Balance sheet: notes and sources

Notes: FY2025–FY2026 from FY26 Appendix 4E. FY2024 cash, equity, accumulated losses and licence carrying value from FY26 statement of changes in equity, cash flow statement and Note 7 movement schedule (opening balances). FY2023–FY2024 debt figures from aggregator (stoxray). FY2026 short-term borrowings of A$85,298 are a small loan following repayment of the A$1.0M facility in Q2 FY26.

Cash flow: notes and sources

Notes: FY2025–FY2026 from FY26 Appendix 4E cash flow statement. FY2023–FY2024 operating cash flow and equity proceeds from aggregator (stoxray) data, labelled there as "proceeds from repurchase of equity" but representing equity issuance. Q4 FY26 operating outflow was A$1.671M (Appendix 4C, 30 July 2026).

Ratios

Notes: Analyst calculations from FY26 Appendix 4E. FY2025 ROE uses average of FY24 equity (A$867k) and FY25 equity (A$660k). n/m = not meaningful given losses or negligible sales. (Ratio table uses n/m text because ratios are not chartable time series.)

Commentary on trends, inflections and drivers

Loss trajectory. Statutory losses fell steadily from A$8.79M (FY22) to A$3.83M (FY25) as the company retreated from the expensive 2021–2023 regulatory push, cut R&D after the TGA withdrawal, and restructured under new management. FY26 reversed that trend, with the loss widening 55% to A$5.93M. The Directors attribute the increase mainly to people and commercialisation costs: employment costs rose A$484k (+14%) to A$3.93M, office and administration rose A$354k (+21%) to A$2.02M (marketing, accreditation, investor relations), and cost of goods sold rose to A$360k as the laboratory began processing clinical samples. R&D expensed actually fell 25% to A$1.04M, reflecting the pivot from development to commercial execution.

The R&D refund distortion. The single largest swing factor in reported results is the timing of the Australian R&D tax incentive refund, which Rhythm recognises as income only when received (cash basis, relating to the prior year's claim). FY25 benefited from a A$3.17M refund (relating to FY24's heavier spend), while FY26 received only A$1.58M (relating to the leaner FY25). Excluding refund income, the underlying pre-refund loss was approximately A$7.0M in FY25 and A$7.5M in FY26 — a more stable picture of the true cost base, with FY26 roughly 8% higher. Investors should expect a further, likely smaller, refund in FY27 relating to FY26's reduced R&D spend.

Revenue inflection — real but tiny. Sales revenue more than tripled to A$85,339 in FY26, with cash receipts from customers of A$72,898. This confirms the end-to-end commercial pathway works but does not yet register against a A$7M+ annual cost base. Gross profit on sales remains negative (−A$275k), which is expected at sub-scale laboratory volumes but signals that volume, not price, is the binding constraint.

Balance sheet repair. FY26 equity raises (A$3.75M placement at A$0.09 in August 2025 and A$5.28M from the underwritten exercise of RHYO options at A$0.20 in April 2026) lifted net assets from A$0.66M to A$3.64M, repaid the A$1.0M loan, and moved working capital from a A$347k deficit to a A$2.72M surplus. Net tangible assets per share turned positive (0.73 cents). However, dilution was significant: shares on issue grew 25% (from 290.3M to 364.1M), and the underwriter received share-based consideration valued at A$1.46M (recorded within capital raising costs), meaning effective raising costs were roughly A$2.0M on A$9.2M gross — about 22% of proceeds.

Liquidity and going concern. The auditor again flagged a material uncertainty relating to going concern. At FY26 operating burn (A$5.23M, or ~A$436k per month), the A$3.36M year-end cash balance represents about 7–8 months of runway before the expected FY26 R&D refund. Management's Q4 FY26 guidance is that cash reserves fund operations through Q4 FY27 — a statement that presumably assumes the R&D refund and some cost discipline, and which implicitly signals a capital raise is likely before or during calendar 2027. The 64.6M RHYOA options (A$0.20, expiring November 2027) represent a potential A$12.9M inflow but are deeply out of the money at ~A$0.08.

Goodwill sensitivity. The A$531k goodwill from the geneType acquisition survived FY26 impairment testing, but the disclosed sensitivity is striking: impairment would be required if revenue growth falls below 170% per year over the three-year forecast period or if the pre-tax discount rate rises from 20% to 20.75%. The headroom is therefore extremely thin, and the auditor designated goodwill carrying value a key audit matter. Separately, the parent entity recorded a A$3.39M impairment of other financial assets (investments in/loans to subsidiaries) within the Deed of Cross Guarantee group — eliminated on consolidation but indicative of how management views recoverability of intercompany funding to the geneType/US operations.

Half-year phasing. H1 FY26 loss was A$2.26M (Appendix 4D), implying a H2 FY26 loss of about A$3.67M — consistent with ramping commercial costs after ColoSTAT launch in December 2025 and the 4Cyte, marketing and GP campaigns in the second half.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment sales revenue (AUD K)

025.185.3

Total income incl. R&D refund and interest (AUD K)

1,6903,3261,741

Segment loss before tax (AUD K)

-6,857-3,829-5,930

Sales revenue YoY growth (%)

——239.6

Contribution of segment to total sales (%)

100100100

Platform Details

PlatformContentsLegal vehicle(s)Revenue disclosure

ColoSTAT

Blood-based colorectal cancer test (5 protein biomarkers); Gen2 multiplex kit; in-house laboratory testing service; Access Program

Rhythm Biosciences Ltd; Vision Tech Bio Pty Ltd; Rhythm Biosciences UK Ltd

—

geneType

Nine polygenic/clinical risk assessment tests; molecular genetics services (DNA extraction, bioinformatics)

RHY GeneType Pty Ltd; IchorDX, Inc. (US)

geneType contributed A$25,126 revenue and a A$1.21M loss from 23 Dec 2024 to 30 Jun 2025 (FY26 Note 8); FY26 split not disclosed

“—” = not publicly disclosed.

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Sales revenue (AUD K)

00025.185.3

R&D tax refund income (AUD K)

———3,166.31,575.9

Interest income (AUD K)

———134.376.4

Total income (AUD K)

—3,0961,6903,326.21,740.7

Cost of goods sold (AUD K)

———224.9360.0

Gross profit on sales (AUD K)

———-199.8-274.6

Employment costs (AUD K)

———3,448.03,932.2

Office and administration (AUD K)

———1,668.02,021.9

R&D costs expensed (AUD K)

———1,383.91,039.9

Depreciation and amortisation (AUD K)

———196.8189.3

Finance expense (AUD K)

———66.774.8

EBITDA (AUD K)

———-3,700.2-5,742.4

Operating income / EBIT excl. net interest (AUD K)

———-3,897.0-5,931.7

Pre-tax income (AUD K)

-8,793.5-8,217.6-6,856.8-3,829.4-5,930.1

Net income (AUD K)

-8,793.5-8,217.6-6,856.8-3,829.4-5,930.1

EPS basic (A$ cents)

-4.19-3.79-3.00-1.42-1.77

EPS diluted (A$ cents)

-4.19-3.79-3.00-1.42-1.77

Dividends per share (A$ cents)

00000

Weighted avg shares (M)

209.9216.8228.6269.3334.2

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

———2,831.84,776.8

Cash and equivalents (AUD K)

——709.51,397.23,355.3

Term deposits (AUD K)

———85.085.0

Short-term borrowings (AUD K)

—85781,000.085.3

Lease liabilities current (AUD K)

———105.486.8

Lease liabilities non-current (AUD K)

———1.975.8

Total debt incl. leases (AUD K)

—1703271,107.3248.0

Net debt (negative = net cash) (AUD K)

———-289.9-3,107.3

Total equity (AUD K)

——867.2659.93,637.2

Goodwill (AUD K)

000531.0531.0

Other intangibles — CSIRO licence (AUD K)

——354.1318.1282.2

Working capital (AUD K)

———-347.42,715.2

Accumulated losses (AUD K)

——38,674.242,503.548,433.6

NTA per share (A$ cents)

———-0.100.73

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD K)

———22.272.9

R&D tax refund received (AUD K)

———3,166.31,575.9

Operating cash flow (AUD K)

—-6,958-6,137-2,921.3-5,233.0

Capex — plant and equipment (AUD K)

———23.225.8

Free cash flow (AUD K)

———-2,944.5-5,258.8

Acquisition payments (AUD K)

000519.80

Equity raised gross (AUD K)

—3,7162,8973,500.19,025.8

Capital raising costs (AUD K)

———219.1536.0

Net borrowings (AUD K)

———1,000.0-1,166.9

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Returns & Leverage Ratios (%)

RatioFY2025FY2026

ROE (% on average equity)

-499-276

ROA (% on average assets)

—-156

ROIC (%)

ROIC (%)n/mn/m

Current ratio (x)

0.843.61

Debt / equity incl. leases (x)

1.680.07

Net debt / EBITDA (x)

Net debt / EBITDA (x)n/mn/m

Interest coverage (x)

n/m

n/m

Asset turnover on sales (x)

—0.02

Cash conversion cycle (days)

n/m

n/m

Operating cash burn per month (AUD K)

243436

Revenue by Region

RegionFY2024FY2025FY2026

Australia (AUD K)

0——

United States (AUD K)

0——

Southeast Asia (AUD K)

00—

United Kingdom (AUD K)

000

Total sales revenue (AUD K)

025.185.3

Platform × Geography Details

Platform × geographyAustraliaUnited StatesSoutheast AsiaUnited Kingdom

ColoSTAT

Commercial (in-house IVD; first sale Mar 2026)

Not launched

Not launched

NHS evaluation; UKCA marked; tech transfer complete

geneType

Commercial (AGRF scale-up partnership)

Commercial (Catch Bio, Cancer IQ; US lab lease acquired)

First clinical sale (Philippines)

Not launched

Share Price and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

1.150.410.060.0540.091

Shares on issue at 30 June (M)

——252.6290.3364.1

Market cap at 30 June (AUD Mn)

——15.215.733.1

Share Price & Returns

HorizonApproximate returnBasis

1-year (Oct 2025 → Sep 2026)

Roughly −10%

~A$0.090 (Nov 2025 option grant-date price) to A$0.081 (29 Sep 2026)

3-year

Roughly −70% or worse

Shares traded near A$0.28+ in October 2023 per Reuters (Feb 2026 high was the highest since 11 Oct 2023)

5-year

Roughly −93%

Shares traded ~A$1.23 in September 2021

52-week range

A$0.075 – A$0.28

Stocklight / Yahoo Finance data, 2026

Valuation Multiples

MultipleRhythmComment

Market capitalisation

~A$29.5M

364.06M shares

Enterprise value

~A$26.4M

Less FY26 net cash of A$3.1M

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales (FY26)

~310x

On A$85k sales

P/B (FY26)

~8.1x

On A$3.64M net assets

Capital Markets

ItemStatus

Analyst coverage

One analyst per Simply Wall St; TipRanks shows most recent rating as Hold with A$0.18 price target (circa April 2026)

Dividend history

No dividends paid since IPO

Dividend policy

None; capital retained for commercialisation

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

A$85k loan (current); lease liabilities A$86.8k (current), A$75.8k (non-current); no long-term debt

Potential equity inflows

64,621,132 RHYOA options at A$0.20 (expiry 30 Nov 2027) ≈ A$12.9M if fully exercised; currently out of the money

Analyst Conclusions

Management guidance

Management has not provided revenue or earnings guidance. The only explicit financial guidance is that cash reserves are expected to fund operations through Q4 FY27 (Q4 FY26 Appendix 4C). Directors expect an FY26 R&D refund and retain the option to scale back activity. Incentive hurdles imply an internal ambition of A$1.5M revenue by June 2027 and A$0.15M from three non-Australian markets.

Consensus expectations

No published consensus revenue or earnings forecasts are available.

Bull case

  1. Infrastructure is complete, so incremental volume drops through. With accreditation, TGA notification, contract manufacturing, a 100+ site collection network and GP software ordering all in place, the fixed-cost base is largely set; each additional A$250 test should improve gross margin from today's negative level.

  2. NHS validation could re-rate the company. Successful completion of the patient-sample phases at the Southern Hub would make ColoSTAT one of very few blood CRC tests independently evaluated within NHS England's screening system, supporting licensing or kit-supply deals well beyond Rhythm's ~A$26M enterprise value.

  3. Public-system economics are compelling. The October 2026 model, comparing a A$250 blood test with a A$3,163 colonoscopy, gives health departments a quantified reason to trial ColoSTAT for colonoscopy triage, potentially unlocking funded volumes in Australia.

Bear case

  1. Commercial traction is not yet visible in the numbers. FY26 sales were A$85k, receipts A$73k, and gross profit negative; reaching the A$1.5M FY27 hurdle requires roughly 17x growth, while goodwill impairment is triggered below 170% annual growth.

  2. Dilution is structural. At ~A$5.2M annual operating burn and A$3.4M cash, another raise appears likely within 12 months, at a share price that has fallen ~70% from its February 2026 high and with a 64.6M out-of-the-money option overhang.

  3. The evidentiary and competitive bar keeps rising. Guardant's Shield has FDA approval, Medicare coverage and ~87,000 tests in 2025; Rhythm relies on a single 2021–2022 Australian study, an in-house IVD pathway and self-pay patients, with no reimbursement in any jurisdiction.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q1 FY27 Appendix 4CLate Oct 2026Customer receipts, test volumes, burn rate
2026 AGMLikely Nov 2026 (date per 29 Sep notice)Board composition, remuneration vote, capital management resolutions
NHS evaluation Phase 2 (analytical testing on patient samples)FY27Performance on NHS samples; next-stage scope
FY26 R&D tax refundH1 FY27Size (likely below FY25's refund given lower R&D)
Additional GP software integrationsFY27Ordering volume impact
Reimbursement engagement (Medicare / state health)FY27Any pilot or funding pathway
geneType US reimbursement strategyFY27Payer progress; US revenue
CFO appointmentFY27Finance leadership stability
Capital raisingLikely H2 FY27Price, size, dilution
H1 FY27 results~17 Feb 2027Revenue run-rate vs A$1.5M hurdle

Concluding analyst verdict

Rhythm Biosciences has done the unglamorous work that its 2021-era valuation skipped. In the past 12 months it has secured laboratory accreditation, NATA approval for the ColoSTAT clinical service, a TGA in-house IVD notification, a US contract manufacturer with fixed pricing, a per-test collection network spanning more than 100 activated sites, electronic GP ordering, a health-economic model, and — most strategically — an NHS England evaluation that has already cleared its technology-transfer phase. Management, now led by a commercially seasoned CEO and an independent MedTech chair, has reframed the company from a single-asset regulatory gamble into a two-platform diagnostics service business. That is genuine progress.

The financial statements, however, describe a business that has proven its pathway rather than its demand. FY26 sales of A$85,339 against a pre-refund loss of roughly A$7.5M, negative gross profit, a going-concern material uncertainty, goodwill headroom that evaporates below 170% annual growth, and a 25% increase in share count in a single year all point to a company whose equity value depends on events that have not yet occurred. The April 2026 ASX query and the post-underwriting share-price slide have also dented the credibility capital that a serial raiser needs.

At an enterprise value near A$26M, the market is pricing ColoSTAT as an option rather than a business — which is a defensible stance. The asymmetry is real: a favourable NHS outcome, a public-hospital pilot, or evidence of sustained GP-driven volume could each justify a multiple of today's valuation, while failure on any of them leaves an under-funded micro-cap facing dilutive raises against well-capitalised blood-test and stool-test incumbents.

Verdict: a high-risk, binary-leaning speculative position. The key evidence to demand over the next two quarters is simple: quarterly customer receipts trending decisively above A$100k and a clean progression of the NHS evaluation. Without both, the bear case dominates.


Principal sources: Rhythm Biosciences FY26 Appendix 4E and Audited Financial Report (27 Aug 2026); Half-Year Report and Appendix 4D (18 Feb 2026); Quarterly Activities Reports and Appendix 4C (23 Jan, 30 Apr, 30 Jul 2026); ASX announcements dated 9 Dec 2025, 10 Dec 2025, 26 Feb 2026, 4 Mar 2026, 2 Jul 2026, 20 Aug 2026, 22 Sep 2026, 7 Oct 2026; Response to ASX Query (14 Apr 2026); geneType acquisition announcements (23 Dec 2024, 15 Jan 2025); Bell Potter Healthcare Conference presentation (Nov 2022); Exact Sciences FY2025 results (13 Feb 2026); Guardant Health FY2025 results (financial media, Feb 2026); market data from Listcorp, Stocklight, InvestSMART, Investing.com, Simply Wall St, TipRanks, stoxray and Reuters; historical coverage from Stockhead, Biotech Daily and Stocks Down Under.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundIndependence

Gavin Fox-Smith

Non-Executive Chairman

Director 2 Dec 2024; Chair from 5 Nov 2025

38-year MedTech career; former MD Australia/NZ and VP Asia Pacific, Johnson & Johnson Medical Devices; former CEO of Omnigon (ostomy care); Chair of ANDHealth; NED of Bowel Cancer Australia and SAN Foundation; former Chair of the Medical Technology Association of Australia; GAICD

Independent

Dr David Atkins

Managing Director and CEO

CEO 13 May 2024; MD 30 Sep 2024

~30 years across pharma, devices and diagnostics; senior roles at Congenica (UK), Veridex (US), Gene Shears (Australia), Johnson & Johnson and Danaher. MBA (Finance), Columbia Business School; PhD Molecular Virology, John Innes Institute; Postgraduate Certificate in Pharmacology, UNSW; BSc, University of East Anglia

Executive

Susan (Sue) MacLeman

Non-Executive Director

31 Jan 2023 (Deputy Chair to 2 Dec 2024)

30+ years as pharma/biotech/medtech executive; former CEO and director of ASX-, AIM- and Nasdaq-listed healthtech companies; B.Pharm (UQ), LLM (Deakin), Master of Marketing (MBS); Fellow and NED of ATSE; member of Commonwealth National Research Infrastructure Advisory Group

Independent

Maureen Baker

Non-Executive Director

27 Aug 2026

Capital markets, investment banking and securities background; boards of Acorn Capital Investment Fund (ASX: ACQ) and Vmoto (ASX: VMT)

Independent (presumed)

Carl Stubbings

Non-Executive Director

27 Aug 2026

Commercial and operational experience across biotech and diagnostics, including commercialising diagnostic products in Australia and internationally

Independent (presumed)

Executive Leadership Team

NameTitleTenureNotes

Dr David Atkins

MD & CEO

Since May 2024

See above

Chief Financial Officer

Vacant / not disclosed

Todd Perkinson resigned 19 Dec 2025

Successor not publicly disclosed in documents reviewed; financial controller role previously held by Guy Carisbrooke (resigned 21 Feb 2025)

Mark Licciardo

Company Secretary

Since 6 Jan 2025

Founder of Mertons Corporate Services (now Acclime Australia); director of Frontier Digital Ventures

Chief Operations Officer

Named in Dec 2024 ColoSTAT Gen2 announcement

——

“—” = not publicly disclosed.

Directors' Remuneration

NameCash salary/feesBonusLeave provisionsSuperannuationEquity-basedTotal% performance-based

D Atkins (MD & CEO)

370,37250,00018,42945,73578,069562,60522.8

G Fox-Smith (Chair)

78,672008,39121,428108,49119.8

S MacLeman (NED)

46,875005,62512,85765,35719.7

O Buttula (former Chair, to 5 Nov 2025)

36,313004,358040,6710

T Perkinson (former CFO, to 19 Dec 2025)

115,0130-4,12413,363-9,048115,2040

Total KMP

647,245

50,000

14,305

77,472

103,306

892,328

—

Directors' Remuneration by Attribute

AttributeStatus

Board size

5 (post 27 Aug 2026)

Independent NEDs

4 of 5

Chair / CEO separation

Yes — independent Non-Executive Chair

Gender

2 women (MacLeman, Baker) of 5 directors (40%)

Board meetings FY26

9 (100% attendance by all serving directors)

Committees

Not detailed in documents reviewed; Corporate Governance Statement (approved 29 Sep 2026) published on company website

Remuneration consultant

None used in FY26

Clawback policy

Yes (applies to CEO incentives)

Related-party transactions

None other than remuneration (FY25, FY26)

Major Shareholders

HolderShares% at time of data% of current 364.06M (approx.)Notes

Otto Buttula (and associated entities)

36,384,57512.810.0

Former Chairman; ceased as director 5 Nov 2025 — current holding not reported post-departure

Michelle Wing

18,117,5006.395.0

Early backer (Wing family linked to IPO)

Fidelity International Ltd

17,511,7346.174.8

Increased stake in Feb and Apr 2025

Loumea Investment Pty Ltd

8,052,5202.842.2

Private investment company (Richard Vom)

Rojo Nero Capital Pty Ltd

—1.49——

Top 25 holders combined

—41.99——

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorSegmentProductRelative positioning

Exact Sciences (Nasdaq: EXAS)

CRC screening (stool DNA)

Cologuard

Global category leader; FY2025 revenue US$3.25B, screening revenue US$2.53B

Guardant Health (Nasdaq: GH)

CRC screening (blood, cfDNA)

Shield

FY2025 revenue US$982M; Shield revenue US$79.7M from ~87,000 tests; FDA-approved blood CRC screening test with Medicare coverage

National FIT programs (e.g., Australia's NBCSP; NHS FIT)

CRC screening (stool immunochemical)

FIT kits

Incumbent standard of care; low-cost but under 50% participation in Australia (per Rhythm's Oct 2026 release)

Colonoscopy providers

CRC diagnosis

Colonoscopy

Gold standard; ColoSTAT positions as triage to reduce unnecessary procedures

Geneoscopy (private)

CRC screening (stool RNA)

ColoSense

US-focused stool-based alternative

Freenome (private)

CRC screening (blood, multiomics)

Blood-based CRC test

—

Epigenomics AG

CRC (blood, methylation)

Epi proColon

Earlier blood test with limited uptake (historical)

Clinical Genomics

CRC recurrence (blood)

COLVERA

Niche recurrence monitoring

GRAIL

Multi-cancer early detection

Galleri

MCED tests could subsume single-cancer blood tests

Myriad Genetics

Polygenic/hereditary risk

RiskScore, MyRisk

Direct geneType competitor in US

Ambry Genetics / Color Health / Genomics plc / Allelica

Polygenic risk

Various PRS offerings

Direct geneType competitors

BCAL Diagnostics (ASX: BDX), INOVIQ (ASX: IIQ)

ASX micro-cap cancer diagnostics

Breast cancer blood tests and others

Peer group for investor capital

Peer Comparison FY2026

MetricRhythm Biosciences (FY26, AUD Mn)Exact Sciences (FY25, USD Mn)Guardant Health (FY25, USD Mn)

Revenue

0.0853,250982

Revenue growth (%)

2401833

Net income

-5.93-208—

Adjusted EBITDA

-5.74400—

CRC screening revenue

~0.085 (incl. geneType)

2,53079.7

Company Snapshot

2017

Founded

Parkville, Australia

Headquarters

SWOT Analysis

Strengths

  • Accredited commercial infrastructure in place: ISO 15189:2022 (Dec 2025), NATA accreditation of ColoSTAT service (Mar 2026), TGA in-house IVD notification accepted (Aug 2026).
  • Capital-light distribution: 4Cyte agreement provides access to 1,000+ collection centres on a per-test basis with no upfront payments; 100+ activated by August 2026.
  • Independent international validation track: NHS Southern Hub completed ColoSTAT technology transfer in September 2026, the first time the test was run outside Rhythm's lab.
  • Low-cost acquisition of a second platform: geneType acquired for A$519,751 cash, bringing nine tests, US infrastructure and NATA-accredited capability.
  • Strengthened balance sheet versus FY25: net assets rose from A$0.66M to A$3.64M; working capital swung from −A$0.35M to +A$2.72M; A$1M debt repaid.
  • Refreshed, experienced board: independent Chair with J&J MedTech pedigree; new NEDs with capital markets (Baker) and diagnostics commercialisation (Stubbings) skills; 100% attendance in FY26.

Weaknesses

  • Negligible revenue: FY26 sales of A$85,339 against an operating cost base above A$7.5M before R&D refunds.
  • Negative gross profit: FY26 COGS A$360k exceeded sales by A$275k.
  • Going-concern material uncertainty: flagged by William Buck in FY26 audit report.
  • Fragile goodwill: impairment triggered if three-year revenue growth falls below 170% per year or discount rate rises 75bp.
  • Regulatory credibility gap: ARTG application withdrawn in March 2023 after missing a TGA deadline; current pathway relies on in-house IVD status.
  • Finance leadership gap: CFO resigned December 2025, with no successor disclosed in documents reviewed.

Opportunities

  • NHS adoption: subsequent evaluation phases on patient samples could open the UK (~24M screening-age population) and broader European markets.
  • Public-hospital triage: the October 2026 health-economic study models reductions in colonoscopy demand at A$250 per test vs A$3,163 per colonoscopy.
  • GP channel scale-up: further GP software integrations beyond MedicalDirector, plus the ~20,000-GP Ausdoc campaign.
  • geneType–ColoSTAT pathway: enhanced CRC risk model (Jan 2026) can feed high-risk patients into ColoSTAT testing.
  • US geneType expansion: Catch Bio and Cancer IQ partnerships; reimbursement strategy under development.
  • Kit-based international licensing: technology transfer success supports a model where third-party labs buy Quansys-made kits from Rhythm.

Threats

  • Scaled blood-based competitors: Guardant's Shield reached ~87,000 tests and US$79.7M in 2025 with Medicare coverage.
  • Stool-based incumbents: Exact Sciences generated US$2.53B in screening revenue in 2025.
  • Funding and dilution risk: shares on issue grew 25% in FY26; runway guided only through Q4 FY27; options overhang of 64.6M RHYOA at A$0.20.
  • Reimbursement uncertainty: ColoSTAT is not funded by Medicare; patient self-pay limits volumes.
  • Disclosure / governance scrutiny: April 2026 ASX query on incomplete disclosure of underwriting termination events.
  • Share price momentum loss: decline from ~A$0.28 (Feb 2026 high) to ~A$0.08 (Sep 2026) constrains future capital-raising terms.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Apr 2025Q3 FY25 Activities Report and Appendix 4CIntegration of geneType under way
Apr 2025Fidelity International increases holding (2.9M shares)Rare institutional support
31 Jul 2025Q4 FY25 Activities Report and Appendix 4CYear-end cash ~A$1.4M
Aug 2025Placement of up to A$3.75M at A$0.09Funding for ColoSTAT launch and geneType commercialisation
29 Aug 2025FY25 Appendix 4E: income A$3.33M, loss A$3.83MLoss narrowed 44% on prior year
Sep 2025FY25 Annual ReportStrategic shift to revenue generation; Gen2 launch targeted late FY26
5 Nov 2025AGM; Otto Buttula retires; Gavin Fox-Smith appointed ChairEnd of founder-era chairmanship
9 Dec 2025US marketing partnership with Catch Bio for geneTypeUS channel expansion
10 Dec 2025NHS Southern Hub to evaluate ColoSTATFirst NHS engagement
Dec 2025Updated ISO 15189:2022 accreditation for Melbourne labRegulatory prerequisite for clinical testing
12 Dec 2025Rhythm initiates commercialisation of ColoSTATShares rose ~26% on the day
19 Dec 2025CFO Todd Perkinson resignsFinance leadership gap
Q2 FY26A$1.571M R&D refund received; A$1M loan fully repaidBalance sheet clean-up
Jan 2026Next-generation geneType CRC risk test delivered; Harvard validation of ovarian modelPlatform enhancement
23 Jan 2026Q2 FY26 Appendix 4C; NATA variation assessment heldCommercial readiness
Early Feb 2026Multi-year Quansys manufacturing agreementShares +79% in the week, highest since Oct 2023
11 Feb 2026First physician enrolled in ColoSTAT Access ProgramCommercial deployment begins
17 Feb 20264Cyte Pathology services agreementAccess to 1,000+ collection centres
18 Feb 2026Half-year report: loss A$2.26MCommercial investment phase
23–25 Feb 2026Trading halt; RHYO options exercise underwritten for A$4.5–6.0MFunding secured (with dilution)
26 Feb 2026NHS England ColoSTAT evaluation commencesInternational validation track
4 Mar 2026geneType Southeast Asia distribution agreement (Philippines)Geographic expansion
9 Mar 2026NATA accredits ColoSTAT clinical testing serviceKey regulatory gate
11 Mar 2026First ColoSTAT clinical test saleFirst ColoSTAT revenue
18 Mar 2026Accelerating commercial rollout; 4Cyte network expanded38 → 78 sites by end-March
30–31 Mar 2026Prospectus; RHYO options underwriting agreementFormal capital process
2 Apr 2026Shortfall notice issued to underwriterOption holders did not fully exercise
14 Apr 2026Response to ASX query letterCompany conceded its 25 Feb summary of underwriting termination events was incomplete
15 Apr 202618.8M new shares quotedUnderwriting shortfall settlement
28 Apr 2026RHYO underwriting update (~A$5.2M)Raise completed
30 Apr 2026Q3 FY26 Appendix 4C; AGRF partnership"Defining quarter" per management
6 May 2026ColoSTAT demonstrates early clinical adoptionRepeat ordering
26 May 2026ColoSTAT Access Program gains momentumClinician support
4 Jun 2026Singapore investor presentationAsian investor outreach
Jun 2026BIO International Convention participationPartnering pipeline
2 Jul 2026Market research complete; ~20,000-GP awareness campaign launchedDemand generation
30 Jul 2026Q4 FY26 Appendix 4C: operating outflow A$1.671M; runway through Q4 FY27Burn rate signal
6 Aug 2026Bioshares 2026 presentationInvestor outreach
20 Aug 2026TGA in-house IVD notification; MedicalDirector live; 100+ sitesCommercial infrastructure complete
26 Aug 2026Maureen Baker and Carl Stubbings appointed NEDs (effective 27 Aug)Board strengthened in capital markets and diagnostics commercialisation
27 Aug 2026FY26 Appendix 4E: sales A$85k; loss A$5.93M; cash A$3.36MGoing-concern uncertainty retained
22 Sep 2026NHS Southern Hub completes ColoSTAT technology transferThird-party lab capability proven
29 Sep 2026FY26 Annual Report; Appendix 4G; AGM date notice; "Board Changes" announcementGovernance filings
7 Oct 2026Health-economic study on ColoSTAT in Australian public hospitalsReimbursement case building

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Sales revenue rose from AUD 0 Mn in FY2022 to AUD 0.1 Mn in FY2026.
Rhythm Biosciences Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Sales revenue00000.1
Cost of goods sold———0.20.4
Gross profit on sales———-0.2-0.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.